Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The Omaha System has been providing a useful clinical documentation structure for health practice, education, and research since 1975. To understand its current applications, we updated a literature review from 2013, using the same descriptors ('Omaha System') which resulted in 559 documents. After applying filters and different forms of screening, 35 papers published from 2012 to 2022 composed the final sample for the review. From its critical analysis we realized that the Omaha System is still a valuable tool for the evaluation of health care outcomes in a variety of settings. Its benefits include promoting communication, supporting evidence-based dec;ision-making, and improving the quality of care and it is interoperable with other classifications and terminologies in healthcare. The use of the Omaha System still enables a consistent integration between patient, community, and health professionals, ensuring the collection and analysis of data that contributes to holistic care in a multidisciplinary approach.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3233/SHTI240235 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Metastatic Breast Cancer mHealth App to Promote Patient-Provider Communication: Protocol for a Usability and Satisfaction Study.
JMIR Res Protoc
September 2025
Department of Health Services Research & Administration, College of Public Health, University of Nebraska Medical Center, Omaha, NE, United States.
Background: With the availability of more advanced and effective treatments, life expectancy has improved among patients with metastatic breast cancer (MBC), but this makes communication with their medical oncologist more complex. Some patients struggle to learn about their therapeutic options and to understand and articulate their preferences. Mobile health (mHealth) apps can enhance patient-provider communication, playing a crucial role in the diagnosis, treatment, quality of life, and outcomes for patients living with MBC.
View Article and Find Full Text PDFPragmatic Comparative Effectiveness Trials in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Multiperspective Qualitative Study.
CHEST Pulm
June 2025
Department of Pulmonary, Critical Care and Sleep Medicine, University of Kansas Medical Center, Kansas City KS.
Background: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) portends a devastating prognosis for patients, with survival typically being < 5 to 8 years after diagnosis. Limited clinical trial data exist to guide treatment strategies, and the efficacy of current strategies-immunomodulation and antifibrotics-remains uncertain. Large randomized controlled trials are costly, but pragmatic trial designs could reduce expenses.
View Article and Find Full Text PDFPacing to pink noise enhances gait recovery from a mechanical perturbation.
J Exp Biol
September 2025
Department of Biomechanics, University of Nebraska at Omaha, Omaha, NE, USA.
Effective locomotion requires physiological systems to adapt to instabilities. While gait perturbation recovery often appears rapid, it is possible that longer-lasting effects may be present. Therefore, this study explored recovery trends of gait dynamics following an experimenter-induced perturbation.
View Article and Find Full Text PDFA 3-month clofazimine-rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial.
Lancet Infect Dis
September 2025
The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Background: Based on results from preclinical and clinical studies, a five-drug combination of isoniazid, rifapentine, pyrazinamide, ethambutol, and clofazimine was identified with treatment shortening potential for drug-susceptible tuberculosis; the Clo-Fast trial aimed to determine the efficacy and safety of this regimen. We compared 3 months of isoniazid, rifapentine, pyrazinamide, ethambutol, and clofazimine, administered with a clofazimine loading dose, to the standard 6 month regimen of isoniazid, rifampicin, pyrazinamide, and ethambutol in drug-susceptible tuberculosis.
Methods: Clo-Fast was a phase 2c open-label trial recruiting participants at six sites in five countries.
The Dilemma of Endomyocardial Biopsy Sampling for Lymphocytic Myocarditis Diagnosis.
Cardiovasc Pathol
September 2025
CVPath Institute, Gaithersburg, MD, USA. Electronic address: